Correlation between serum miR-34a and miR-182 levels before PCI and postoperative contrast-induced nephropathy occurrence in elderly patients with acute coronary syndrome

doi:10.11958/20231183

Abstract

Abstract:

Objective To investigate the relationship between serum microRNA (miR)-34a and miR-182 levels before percutaneous coronary intervention (PCI) and postoperative contrast-induced nephropathy (CIN) occurrence in elderly patients with acute coronary syndrome (ACS). Methods A total of 146 elderly patients with ACS who underwent PCI were included. Clinical data of ACS patients were collected. The indexes of preoperative blood lipid and renal function were detected by automatic biochemical analyzer. Serum levels of miR-34a and miR-182 were determined by real time fluorescence quantitative PCR. Patients were divided into the CIN group (20 cases) and non-CIN group (126 cases) according to whether CIN occurred after PCI. Clinical data, preoperative blood lipids, renal function indexes, serum miR-34a, miR-182, postoperative serum creatinine (Scr) and glomerular filtration rate (eGFR) were compared between the CIN group and the non-CIN group. The correlation of preoperative serum miR-34a, miR-182, postoperative Scr, and eGFR in elderly patients with ACS were analyzed, and factors affecting the occurrence of CIN in elderly patients with ACS after PCI were also analyzed. Receiver operating characteristic (ROC) curve was used to evaluate the predictive value of preoperative serum miR-34a and miR-182 levels for occurrence of CIN in elderly patients with ACS after PCI. Results Preoperative serum miR-34a and miR-182 levels and postoperative Scr levels were higher in the CIN group than those in the non-CIN group, while postoperative eGFR level was lower than those in the non-CIN group (P<0.05). Preoperative serum miR-34a and miR-182 were positively correlated with postoperative Scr, and negatively correlated with postoperative eGFR in elderly patients with ACS (P<0.05). Preoperative serum miR-34a was positively correlated with miR-182 (P<0.05). The increase of serum miR-34a and miR-182 levels before surgery were an independent risk factor for occurrence of CIN in elderly patients with ACS after PCI (P<0.05). The area under curve (AUC) of preoperative serum miR-34a, miR-182 and their combination in predicting postoperative occurrence of CIN in elderly ACS patients after PCI were 0.881, 0.888, and 0.964, respectively. The AUC predicted by the two combined was higher than that predicted by each separately (P<0.05). Conclusion The increased serum levels of miR-34a and miR-182 before surgery are risk factors for occurrence of CIN in elderly patients with ACS after PCI, and the combination of the two can effectively predict the occurrence of CIN.

Key words: acute coronary syndrome, percutaneous coronary intervention, microRNA-34a, microRNA-182, contrast-induced nephropathy

CLC Number:

R541.4，R692.9

Figures/Tables 7

References 22

[1]	DAMLUJI A A, FORMAN D E, WANG T Y, et al. Management of acute coronary syndrome in the older adult population:a scientific statement from the american heart association[J]. Circulation, 2023, 147(3):32-62. doi:10.1161/CIR.0000000000001112.
[2]	ANAYAT S, MAJID K, NAZIR H S, et al. Meta-analysis on the efficacy of high-dose statin loading before percutaneous coronary intervention in reducing no-reflow phenomenon in acute coronary syndrome[J]. Am J Cardiol, 2023, 195(1):9-16. doi:10.1016/j.amjcard.2023.02.024.
[3]	IRANNEJAD K, VAKHSHOORI M, KHOUBYARI R, et al. Contrast removal from coronary sinus for prevention of contrast-induced nephropathy:a review[J]. Future Cardiol, 2023, 19(5):283-299. doi:10.2217/fca-2023-0034.
[4]	POKHREL A, SHARMA A, KHATIWADA D, et al. Contrast-induced nephropathy among patients administered with contrast material at a tertiary care centre:a descriptive cross-sectional study[J]. JNMA J Nepal Med Assoc, 2023, 61(259):224-227. doi:10.31729/jnma.8065.
[5]	杨娟, 张厚芬, 吴松, 等. LncRNA OIP5-AS1调节miR-25-3p/SOX4轴对高糖诱导的人肾小管上皮细胞生物学过程的影响[J]. 天津医药, 2023, 51(2):131-138.
	YANG J, ZHANG H F, WU S, et al. Effects of lncRNA OIP5-AS1 regulating miR-25-3p/SOX4 axis on the biological process of human renal tubular epithelial cells induced by high glucose[J]. Tianjin Med J, 2023, 51(2):131-138. doi:10.11958/20220849.
[6]	LIANG Y, LIU H, ZHU J, et al. Inhibition of p53/miR-34a/SIRT1 axis ameliorates podocyte injury in diabetic nephropathy[J]. Biochem Biophys Res Commun, 2021, 559(1):48-55. doi:10.1016/j.bbrc.2021.04.025.
[7]	孙瑶, 孙琨. β2-MG miR-182 BUN在老年慢性肾功能衰竭中的表达及相关性研究[J]. 河北医学, 2022, 28(5):754-759.
	SUN Y, SUN K. Expression and correlation studies of β2-MG miR-182 BUN in elderly chronic renal failure[J]. Hebei Medicine, 2022, 28(5):754-759. doi:10.3969/j.issn.1006-6233.2022.05.011.
[8]	中国医师协会急诊医师分会, 国家卫健委能力建设与继续教育中心急诊学专家委员会, 中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 中华急诊医学杂志, 2019, 28(4):421-428.
	Chinese Medical Doctor Association Emergency Physicians Branch, National Health Commission Capacity Building And Continuing Education Center Emergency Medicine Expert Committee, China Medical Care International Exchange Promotion Association Emergency Branch. Guidelines for rapid emergency diagnosis and treatment of acute coronary syndrome(2019)[J]. Chinese Journal of Emergency Medicine, 2019, 28(4):421-428. doi:10.3760/cma.j.issn.1671-0282.2019.04.003.
[9]	陶舒敏, 张龙江, 吴献华. 《欧洲泌尿生殖放射学会对比剂安全委员会2018年指南》对比剂使用后急性肾损伤部分的解读[J]. 国际医学放射学杂志, 2019, 42(5):593-597.
	TAO S M, ZHANG L J, WU X H. Interpretation of 2018 guidelines of contrast media safety committee(CMSC)of the european society of urogenital radiology on post-contrast acute kidney injury[J]. International Journal of Medical Radiology, 2019, 42(5):593-597. doi:10.19300/j.2019.B7427.
[10]	GHERASIE F A, POPESCU M R, BARTOS D. Acute coronary syndrome:disparities of pathophysiology and mortality with and without peripheral artery disease[J]. J Pers Med, 2023, 13(6):944-962. doi:10.3390/jpm13060944.
[11]	HAN K, SHI D, YANG L, et al. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. Ann Med, 2022, 54(1):1667-1677. doi:10.1080/07853890.2022.2083671.
[12]	CHEN F, LU J, YANG X, et al. Different hydration methods for the prevention of contrast-induced nephropathy in patients with elective percutaneous coronary intervention:a retrospective study[J]. BMC Cardiovasc Disord, 2023, 23(1):323-330. doi:10.1186/s12872-023-03358-w.
[13]	FU H, ZHANG J, ZHANG H, et al. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency[J]. Perfusion, 2021, 36(6):603-609. doi:10.1177/0267659120957856.
[14]	BERGAMI M, FABIN N, CENKO E, et al. MicroRNAs as potential biomarkers in coronary artery disease[J]. Curr Top Med Chem, 2023, 23(6):454-469. doi:10.2174/1568026623666221221124530.
[15]	TANASE D M, GOSAV E M, OUATU A, et al. Current knowledge of microRNAs (miRNAs) in acute coronary syndrome(ACS):ST-elevation myocardial infarction(STEMI)[J]. Life(Basel), 2021, 11(10):1057-1077. doi:10.3390/life11101057.
[16]	陆谦, 杨旭, 李静, 等. IgA肾病患者外周血miR-34a水平及其与肾功能的关系分析[J]. 中国中西医结合肾病杂志, 2020, 21(7):616-618.
	LU Q, YANG X, LI J, et al. Analysis of peripheral blood miR-34a level and its relationship with renal function in patients with IgA nephropathy[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2020, 21(7):616-618. doi:10.3969/j.issn.1009-587X.2020.07.016.
[17]	DU Y, NING J Z. MiR-182 promotes ischemia/reperfusion-induced acute kidney injury in rat by targeting FoxO3[J]. Urol Int, 2021, 105(7/8):687-696. doi:10.1159/000515649.
[18]	郭艳梅, 李君娥, 孙慧, 等. 脓毒症并发急性肾损伤患儿的血清miR-182-5p、miR-21-3p表达变化及其临床意义[J]. 山东医药, 2021, 61(30):29-33.
	GUO Y M, LI J E, SUN H, et al. Expression and clinical significance of serum miR-182-5p and miR-21-3p in children with sepsis compli-cated with acute kidney injury[J]. Shandong Medical Journal, 2021, 61(30):29-33. doi:10.3969/j.issn.1002-266X.2021.30.007.
[19]	GUO M, GAO J, JIANG L, et al. Astragalus polysaccharide ameliorates renal inflammatory responses in a diabetic nephropathy by suppressing the TLR4/NF-κB pathway[J]. Drug Des Devel Ther, 2023, 17(1):2107-2118. doi:10.2147/DDDT.S411211.
[20]	SHIBATA R, TAGUCHI K, KAIDA Y, et al. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus[J]. Clin Exp Nephrol, 2023, 27(1):44-53. doi:10.1007/s10157-022-02277-y.
[21]	张颢曦, 范晓兰, 杨敏. miR-34a与糖尿病肾病肾小管间质纤维化发病机制的研究进展[J]. 广西医学, 2022, 44(22):2679-2683.
	ZHANG H X, FAN X L, YANG M. Research progress of miR-34a and pathogenesis of tubulointerstitial fibrosis in diabetes nephropathy[J]. Guangxi Medical Journal, 2022, 44(22):2679-2683. doi:10.11675/j.issn.0253-4304.2022.22.20.
[22]	崔增林, 刘高瑞, 臧海洋, 等. miR-182-5p调控FABP4表达对草酸钙结晶性肾损伤的影响[J]. 热带医学杂志, 2022, 22(6):756-762,896.
	Z L, LIU G R, ZANG H Y, et al. Effect of miR-182-5p regulating FABP4 expression on calcium oxalate crystal kidney injury[J]. Journal of Tropical Medicine, 2022, 22(6):756-762,896. doi:10.3969/j.issn.1672-3619.2022.06.004.

基因名称	引物序列（5′→3′）	产物大小/bp
miR-34a	上游：CGGTATCATTTGGCAGTGTCT	46
miR-34a	下游：GTGCAGGGTCCGAGGT	46
miR-182	上游：TTTGGCAATGGTAGAACTCACACT	90
	下游：GCTTTGGCAATGGTAGAACTCACACT	90
U6	上游：CGCTTCGGCAGCACATATAC	139
	下游：AAAATATGGAACGCTTCACGA	139

基因名称	引物序列（5′→3′）	产物大小/bp
miR-34a	上游：CGGTATCATTTGGCAGTGTCT	46
miR-34a	下游：GTGCAGGGTCCGAGGT	46
miR-182	上游：TTTGGCAATGGTAGAACTCACACT	90
	下游：GCTTTGGCAATGGTAGAACTCACACT	90
U6	上游：CGCTTCGGCAGCACATATAC	139
	下游：AAAATATGGAACGCTTCACGA	139

组别	n	性别（男/女）	年龄/岁	BMI/（kg/m²）	高血压（是/否）	糖尿病（是/否）	高脂血症（是/否）	对比剂用量/mL	TC/（mmol/L）
非CIN组	126	68/58	70.10±7.53	23.57±2.48	50/76	55/71	51/75	155.29±26.84	4.43±0.61
CIN组	20	12/8	70.17±7.58	24.07±2.26	12/8	7/13	6/14	158.47±30.33	4.37±0.59
χ²或t		0.254	0.039	0.847	2.916	0.529	0.796	0.483	0.410
组别	TG/（mmol/L）			HDL-C/（mmol/L）	LDL-C/（mmol/L）		Scr/（μmol/L）	BUN/（mmol/L）	UA/（μmol/L）
非CIN组	1.45±0.36			0.91±0.21	3.11±0.56		64.01±8.04	5.23±1.05	257.34±43.59
CIN组	1.49±0.34			0.89±0.18	3.19±0.61		63.59±7.62	5.17±1.02	262.54±46.07
χ²或t	0.465			0.403	0.586		0.219	0.238	0.492

组别	n	性别（男/女）	年龄/岁	BMI/（kg/m²）	高血压（是/否）	糖尿病（是/否）	高脂血症（是/否）	对比剂用量/mL	TC/（mmol/L）
非CIN组	126	68/58	70.10±7.53	23.57±2.48	50/76	55/71	51/75	155.29±26.84	4.43±0.61
CIN组	20	12/8	70.17±7.58	24.07±2.26	12/8	7/13	6/14	158.47±30.33	4.37±0.59
χ²或t		0.254	0.039	0.847	2.916	0.529	0.796	0.483	0.410
组别	TG/（mmol/L）			HDL-C/（mmol/L）	LDL-C/（mmol/L）		Scr/（μmol/L）	BUN/（mmol/L）	UA/（μmol/L）
非CIN组	1.45±0.36			0.91±0.21	3.11±0.56		64.01±8.04	5.23±1.05	257.34±43.59
CIN组	1.49±0.34			0.89±0.18	3.19±0.61		63.59±7.62	5.17±1.02	262.54±46.07
χ²或t	0.465			0.403	0.586		0.219	0.238	0.492

组别	n	miR-34a	miR-182
非CIN组	126	1.01±0.12	1.02±0.09
CIN组	20	1.47±0.33	2.35±0.52
t		11.659^＊＊	26.737^＊＊